AVDL Overview
Upcoming Projects (AVDL)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AVDL)
-
A second view: Discussing the recent label expansion of LUMRYZ (sodium oxybate), for the treatment of cataplexy in patients over the age of 7.
Ticker: AVDL
Executed On: Nov 22, 2024 at 11:00 AM EST -
Discussing the recent label expansion of LUMRYZ (sodium oxybate), for the treatment of cataplexy in patients over the age of 7.
Ticker: AVDL
Executed On: Nov 06, 2024 at 03:00 PM EST -
A Third Look: Investigating the recent post-approval data on LUMRYZ and Xywav in patients with narcolepsy presented at World Sleep 2023.
Tickers: AVDL, JAZZ
Executed On: Jan 04, 2024 at 04:30 PM EST -
A Second Look: Investigating the recent post-approval data on LUMRYZ and Xywav in patients with narcolepsy presented at World Sleep 2023.
Tickers: AVDL, JAZZ
Executed On: Dec 21, 2023 at 05:15 PM EST -
Investigating the recent post-approval data on LUMRYZ and Xywav in patients with narcolepsy presented at World Sleep 2023.
Tickers: AVDL, JAZZ
Executed On: Nov 03, 2023 at 01:00 PM EDT -
A Second Opinion: Discussing the prescribing patterns of LUMRYZ (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
Ticker: AVDL
Executed On: Aug 16, 2023 at 05:30 PM EDT -
A second look: Discussion of therapeutic options in NT1 (Narcolepsy Type 1) and Orexin agonists
Tickers: JAZZ, TAK, AVDL, HRMY
Executed On: Aug 10, 2023 at 01:30 PM EDT -
Discussion of therapeutic options in NT1 (Narcolepsy Type 1) and Orexin agonists
Tickers: TAK, JAZZ, AVDL, HRMY
Executed On: Aug 09, 2023 at 05:30 PM EDT -
Discussing the prescribing patterns of LUMRYZ (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
Ticker: AVDL
Executed On: Aug 09, 2023 at 03:30 PM EDT -
Discussing the recent FDA approval of LUMRYZ (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy.
Ticker: AVDL
Executed On: May 05, 2023 at 01:00 PM EDT -
A Second Opinion: Discussing the recent FDA approval of LUMRYZ (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy.
Ticker: AVDL
Executed On: May 05, 2023 at 11:00 AM EDT -
A Third Opinion: Discussing the recent FDA approval of LUMRYZ (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy.
Ticker: AVDL
Executed On: May 05, 2023 at 10:15 AM EDT -
A Second View: Discussing the potential of FT218 and Xyrem/Xywav in treating patients with Narcolepsy
Tickers: JAZZ, AVDL
Executed On: Mar 29, 2022 at 01:30 PM EDT -
Discussing the potential of FT218 and Xyrem/Xywav in treating patients with Narcolepsy
Tickers: JAZZ, AVDL
Executed On: Mar 29, 2022 at 10:00 AM EDT
Upcoming & Overdue Catalysts (AVDL)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (AVDL)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
